drugset / Trial / NCT01103609

Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01103609

Phase 1 Completed 16 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics and Pharmacodynamics of Warfarin in T2DM patients.

Timeline

Start
2010-04
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral
Subject Warfarin Small molecule Oral